SEC-sourced researchBeta
NVCR
NovoCure Ltd
Company comparison ↗
Data passport
- CIK
- 0001645113
- Exchange
- Nasdaq
- Business activity
- — · SIC 3841
- Financial inputs
- 6/6
- Filing date
- Oct 1, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 509,338,000.0000 | Feb 26, 2026 |
| December 2024 | 605,220,000.0000 | Feb 26, 2026 |
| December 2025 | 655,353,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 655,353,000.0000 | -136,227,000.0000 | -49,031,000.0000 | 804,326,000.0000 | 463,860,000.0000 | Feb 26, 2026 |
| December 2024 | 605,220,000.0000 | -168,627,000.0000 | -26,369,000.0000 | 1,240,784,000.0000 | 880,605,000.0000 | Feb 26, 2026 |
| December 2023 | 509,338,000.0000 | -207,043,000.0000 | -73,336,000.0000 | — | — | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $655.35M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenues | $605.22M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$136.23M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$49.03M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $804.33M | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $463.86M | December 2025 | Feb 26, 2026 | 10-K |